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Abstract
Gliomas develop genetic traits to rapidly form aggressive phenotypes. Hence, man-
agement of gliomas is complicated and difficult. Besides genetic aberrations such as 
oncogenic copy number variation and mutations, alternative mRNA splicing triggers 
prooncogenic episodes in many cancers. In gliomas, we found alternative splicing at 
the KCNMA transcription process. KCNMA1 encodes the pore forming α-subunit of 
large-conductance calcium-activated voltage-sensitive potassium (BK
Ca
) channels. These 
channels play critical role in glioma invasion and proliferation. We identified a novel 
KCNMA1 mRNA splice variant with a deletion of 108 base pairs (KCNMA1v) mostly 
overexpressed in high grade gliomas. We found that KCNMA1 alternative pre-mRNA 
splicing enhanced glioma growth, progression and diffusion. The role of KCNMA1 and 
its splicing as a critical posttranscriptional regulator of BK
Ca
 channel expression is pre-
sented in this chapter. Our research implies that high grade gliomas express KCNMA1v 
and BK
Ca
 channel isoform to accelerate growth and transformation to glioblastoma 
multiforme (GBM). We demonstrated that tumors hardly develop in mice injected with 
KCNMA1v transfected cell line expressing short-hairpin RNA (shRNA) compared to 
mice injected with KCNMA1v transected glioma cells. We conclude that targeting the 
KCNMA1 variants may be a clinically beneficial strategy to prevent or at least slow down 
glioma transformation to GBM.
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 channels in glioma
Brain tumors are the most common type of solid tumors. In the United States, an estimated 
20,000 new primary brain tumor cases are reported [1]. The most common form of malig-
nant glioma is glioblastoma multiforme (GBM). The treatment of brain tumors is highly com-
plicated due to their highly aggressive phenotypic and genotypic changes [2]. The median 
survival among GBM patients is only 15 months or less [3]. GBM contains heterogeneous sub-
populations of glioma and other mixed supporting cells that are cancerous cells. They have the 
intrinsic ability that adapt in the brain tumor microenvironment and invade the normal brain. 
Gene expression profiling studies have identified many genes that have distinct expression 
patterns among different histological types and grades of gliomas [4]. The response of “normal 
cells” to malignant transformation involves changes in gene expression and is thought to be 
regulated by transcription [5]. The potassium ion channels are implicated in the malignant 
transformation to a higher grade in several cancers [5–7]. For example, we reported that low-
grade gliomas might undergo certain epigenetic changes to develop into a GBM [8].
The physiological features of BK
Ca
 channels also known as maxi K or BK channels are well 
described [6–9]. These channels are unique since its activity is triggered by depolarization 
and enhanced by an increase in μM range of cytosolic calcium (Figure 1). The BK
Ca
 channels 
provide a crucial link between the metabolic and electrical states of cells. The BK
Ca
 channel 
overexpression was observed in biopsies of patients with malignant gliomas compared with 
nonmalignant human cortical tissues and the level of expression correlated positively with 
increased malignancy [7]. Studies have shown the importance of BK
Ca
 channels in brain tumor 
biology [5]. Lastly, BK
Ca
 currents in glioma cells are more sensitive to intracellular [Ca2+] com-
pared to BK
Ca
 channels in healthy glial cells [9, 10].
Figure 1. BK
Ca
 channel is a tetramer of four monomeric pore-forming alpha-subunits encoded by KCNMA1. The seven 
transmembrane channels S0 to S6 are voltage-sensing domains, S1 to S4 channels form pore domain, S5 is a selectivity 
filter, and S6 is a extracellular N-terminal segment. The cytoplasmic C-terminal domain has RCK1 and RCK2 (with 
calcium bowl) segments.
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2. Diverse role of KCNMA1 in glioma
KCNMA1-encoded BK
Ca
 channel plays a pivotal role in cancer cell proliferation. Amplification 
of KCNMA1 was observed in breast, ovarian, and endometrial cancer with the highest preva-
lence in invasive ductal breast cancers and serous carcinoma of ovary and endometrium (3–7%) 
and gliomas. KCNMA1 amplification was significantly associated with high tumor stage, high-
grade, high tumor cell proliferation, and poor prognosis. Due to the large number of protein 
interactions and activating factors influencing BK
Ca
 channel function, intracellular Ca2+, mem-
brane voltage, pH, shear stress, carbon monoxide, phosphorylation states, and steroid hormones, 
it is generally difficult to predict its direct role in a given tissue. However, in many diseases 
including cancers, defective regulation and/or expression of BK
Ca
 channels have repeatedly been 
associated with altered cell cycle progression [11], cell proliferation [11], and cell migration [11]. 
These altered cell functions are implicated in development of malignancy [11].
3. KCNMA1: STRING analysis
In order to understand the possible interactions of KCNMA1 with other genes and molecules, 
we used the tool STRING 9.1. It is a database consisting of known and possible protein– 
protein interactions with a gene of interest. The gene may have a direct (physical) or indirect 
(functional) association with other molecules. With this tool we can easily identify possible 
interaction of KCNMA1 with other associated molecules. We can derive detailed information 
Figure 2. STRING 9.1 software-derived possible association of KCNMA1 with top 20 most interacting genes.
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Figure 3. High-grade glioma cells, U-87 MG were transfected to make stable cell line over-expressing KCNMA1. In 
addition, we transfected U-87 MG cells with shKCNMA1; this suppressed basal KCNMA1 expression. A microarray 
was performed on these cells. The heat map shows the differential expression of genes that were directly or indirectly 
affected by upregulation or down regulation of KCNMA1. We found 8102 and 7259 significant features at p < 0.05, 
respectively, for overexpression and suppression of KCNMA1. From these, features having at least a signal value of 255 
were selected to reduce false positives (false discovery rate < 0.0079).
of the protein being investigated as well as its associated molecules, crystal structure of the 
proteins with its PDB ID, and combined score [confidence score, neighborhood score, fusion 
score, homology score] on the basis of some parameters like experimental results, text-mining, 
co expression, databases, and co-occurrence (Figure 2).
4. Possible KEGG pathway following activation and suppression of 
KCNMA1 in glioma cells
Glioma cell line U-87 MG was obtained from the American Type Culture Collection 
(Manassas, VA) and cultured in MEM supplemented with 10% FBS and 0.1 mM nonessential 
amino acids. Cells were maintained at 37°C in 5% CO
2
. In order to study the biological signifi-
cance of up- and down-regulation of KCNMA1 on associated genes, we performed microar-
ray using the Affymetrix Human Genome U133 Plus 2.0. Array analyses of U-87 MG cell lines 
where KCNMA1 was either overexpressed or suppressed showed significant changes in genes 
involved in cell proliferation, angiogenesis, cell cycle, and invasion (Figure 3). Class com-
parison tests indicated significant changes in global expression patterns. Twenty genes highly 
downregulated by suppression but upregulated by overexpression of KCNMA1 or vice versa 
are shown in Figure 3. This data support our rationale that KCNMA1 plays a critical role in 
the above cellular processes.
Array analyses of U-87 MG cell lines where KCNMA1 was either overexpressed or suppressed 
showed significant changes in genes involved in cell proliferation, angiogenesis, cell cycle, 
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and invasion (Figure 4; see arrows). Cluster analysis of 476 transcripts that are altered in 
opposite directions by expressing KCNMA1 gene up and down in U-87 cells. These tran-
scripts were identified from the significantly altered genes by ANOVA at p < 0.05, and the 
fold-change thresholds such that one of KCNMA1 up or down altered the gene expression by 
twofold and the other altered it at least by 1.5-fold in the opposite direction.
5. KCNMA1 splicing in glioma
The KCNMA1 encodes the pore-forming α-subunits of large-conductance Ca2+-activated K+ 
(BKCa) channels. More than 20 variants of this gene are associated with alternative splicing 
at ten or more different sites [12, 13], while majority of the splice sites are located in the large 
cytoplasmic domain. This domain is called the C-terminal half of the channel that contains 
multiple Ca2+ binding sites [14–16]. Gating properties and kinetics with regard to the voltage 
and Ca2+ dependence of gating are altered by alternative splicing in these regions [17–19]. 
Expressions of different BK
Ca
 isoforms have been implicated in auditory processing [20] and 
alter the sensitivity of BK
Ca
 to modulation by phosphorylation [21] and other processes [22]. 
However, the role of BK
Ca
 isoforms in cancer is now being investigated [23]. More specifically, 
KCNMA1 is altered in a wide variety of cancers, and their overexpression liked to increased 
malignancy in gliomas [4–7]. The BK
Ca
 protein isoform transcribed by its alternatively spliced 
mRNA in cancer cells is known as likely to respond differently to changes in intracellular 
Figure 4. Cluster analysis of 62 genes altered by twofold in opposite directions by expressing KCNMA1 gene up and 
down in U-87 cells. These transcripts were identified from the significantly altered genes by ANOVA at p < 0.05.
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calcium ([Ca2+]i) and membrane potential. We and others have demonstrated that BK
Ca
 chan-




 channels show a variety of electrophysiological properties due to alternative splicing 
of their α-subunits. In glioma cells, Liu et al. [6] reported that BK
Ca
 channels exhibit distinct 
electrophysiological properties due to alternate splicing of its α-subunits. These BK
Ca
 variants 
showed higher Ca2+ sensitivity in glioma cells compared to BK
Ca
 channels present in normal 
glial cells. The amplified sensitivity to intracellular [Ca2+i] was shown in a novel splice isoform 
(gBK) of hSlo, the gene that encodes the α-subunits, specifically expressed in glioma [6]. We 
have recently shown (submitted for review) that KCNMA1 that encodes α-subunit (pore form-
ing) of BK
Ca
 channel undergoes specific splicing at mRNA to form a variant (KCNMA1v) that 
encodes for a novel BK
Ca
 channel isoform only in glioblastoma multiforme (GBM). Other types 
of Ca2+-activated K+ channels such as intermediate (IKCa) and small (SKCa) [10] have been char-
acterized in human glioma cells, but their roles in brain tumor biology are yet to be explored.
The alternative RNA splicing might increase protein expression levels and functions. In can-
cer, it was shown that abnormal mRNA splicing often leads to tumor-promoting splice vari-
ants that are translated into activated oncogenes or inactivated tumor suppressors [26, 27]. 
Interestingly, the brain appears to have maximum alternative splicing of exons [28]. The pres-
ent knowledge suggests that alternative or aberrant pre-mRNA splicing results in oncopro-
teins with diverse functions in the development, progression, and dispersal of glioma cells 
[29, 30]. Further, genomic studies have shown that gliomas often have splice isoforms than in 
normal brain [30]. For instance, KCNMA1 was shown to undergo alternative pre-mRNA splic-
ing at several sites in humans and mice [31, 32] to generate physiologically diverse BK
Ca
 chan-
nels. These altered BK
Ca
 channels respond differently to calcium/voltage changes. Often, these 
channels show abnormal regulation of cellular signaling pathways in glioma cells [13, 19]. 
Hence, the cause–effect of KCNMA1 splicing in functional modification of BK
Ca
 channels in 
brain tumors is a matter of great interest.
We have described an unknown KCNMA1 mRNA splice variant with a deletion of 108 base pairs 
of exon 22 (KCNMA1v) between the S9 and S10 protein subunits (C-terminus) overexpressed 
in high-grade gliomas. This serendipitous finding prompted to study the role of KCNMA1v 
as a critical posttranscriptional regulator of BK
Ca
 channel isoform expression and altered chan-
nel function in gliomas (submitted for review). The complex interaction between various ions 
and their respective ion channels at the invadopodia of the malignant gliomas is speculated to 
explain some of the invasive properties of gliomas [24, 25]. The role of various ions and their 
respective ion channels in glioma is recently well documented [33]. Among many ion channels, 
BK
Ca
 channels have many known spliced variants. Liu et al. have initially described a spliced 
variant, glioma BK (gBK), channel in human glioma cells [6]. Inherited and acquired changes 
in pre-mRNA splicing have been shown to play a significant role in human disease develop-
ment (pre-mRNA splicing and human disease [29]. Venables et al. [34] showed that alternative 
splicing of pre-mRNA increases the diversity of protein functions in ovarian and breast cancer 
samples. Specifically, they found that expression of FOX2 was downregulated in ovarian cancer 
and its splicing is altered in breast cancer samples affecting cell proliferation.
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However, studies on the association of changes in gene splicing pattern and malignancy are 
rare. However, few studies have shown the presence of BK
Ca
 channels at the invadopodia 
of the malignant gliomas that lead to speculation that these channels may help the invasive 
properties of gliomas. A recent study found a clinical relevance where the investigators found 
T cells derived from GBM patients who were sensitized to the gBK peptide could also kill 
target cells expressing gBK. This study shows that peptides derived from cancer-associated 
ion channels maybe useful targets for T-cell-mediated immunotherapy [23]. Several sites of 
alternative pre-mRNA splicing of KCNMA1 have been described, and majority of them are 
located within the intracellular C-terminal domain of the channel [19]. In the past a novel 
splice variant of KCNMA1 (gBK) with an additional 34-amino-acid exon at splice site 2 in the 
C-terminal has already been described in gliomas [6].
In addition to the above studies, we present herein the cloning, functional characterization, 
and splicing of a novel KCNMA1 splice variant. KCNMA1 encodes the alpha-subunit of 
human BK
Ca
 channels and is known to form BK
Ca
 channel isoforms. Here, we report hitherto 
unknown KCNMA1 splice variant, which has a 108-base-pair deletion at the splice site on 
one of its exons, which we termed as KCNMA1v. More importantly, KCNMA1v expression 
correlates positively with the relative degree of malignancy of the glioma cell lines (under 
publication). Moreover, we found that KCNMA1v was expressed only in high-grade glioma 
samples and not in normal brain tissues as evidenced by examination of human biopsy speci-
mens (under publication). Expression of KCNMA1v in HEK (null type) revealed that the phar-
macological and biophysical properties of the variant were consistent with the properties of 
wild-type KCNMA1 gene in glioma cells suggesting that KCNMA1v is likely to encode the 
principal wild-type BK
Ca
 channels (under publication). Although we have not separated wild-
type and splice variant isoform for sequence and structure analysis, the biological properties 
of both wild-type and isoform protein appear to be similar. However, when overexpressed in 
glioma cell line (under publication), the variant showed distinct biological properties such as 
enhanced Ca2+ sensitivity at physiologically relevant [Ca2+]i levels (under publication).
Progression of brain tumor from localized, slow-growing tumors to more aggressive brain 
tumors capable of invading the surrounding brain most likely involves a series of stepwise 
biological events [35]. For example, miR-182 was found to be a valuable marker of glioma 
progression and that high miR-182 expression is associated with poor prognosis [36]. Such 
a multistep process of tumorigenesis has been proposed to involve a series of mutational 
events which ultimately lead to development and progression of neoplasia [35]. Aberrant 
pre-mRNA splicing is an important factor in tumor progression and has been proposed to 
result in the loss of a normal pathway of differentiation, which could lead to tumor progres-
sion. Several studies have implicated BK
Ca
 channel expression to oncogenic cell transforma-
tion [37, 38]. Increased activity of BK
Ca
 channels appeared to be required for the mitogenic 
stimulation of non-transformed cells and may play a role in cell proliferation [39]. Consistent 
with the above studies, we show that KCNMA1v-induced effects promote proliferation in gli-
oma cell lines when the variant was overexpressed. The upregulation of KCNMA1v in glioma 
cell lines provides an opportunity to determine variant-specific changes that enhance glio-
magenesis in vivo. The overexpression of KCNMA1v resulted in increased proliferation in 
glioma cell lines. It has also been suggested that cell invasion into narrow brain spaces may 
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require tumor cells to shrink and squeeze through tight interstitial space [40]. Cell shrinkage 
requires the efflux of K+ and Cl− ions [41], and BK
Ca
 channels may serve as pathway for regu-
lated K+ efflux [42]. Consistent with these findings, the overexpression of KCNMA1v increased 
the invasion potential of glioma cells (under publication). The role of BK
Ca
 channels in cell 
migration was already described [43]. The changes in proliferation and migration of cells 
over-expressing KCNMA1v were mostly attributed to increased levels of KCNMA1 and BK
Ca
 
channel protein expression in transfected cells. Additionally, overexpression of KCNMA1v 
in glioma cells may assist them to diffusely invade the normal brain. Due to this phenom-
enon, GBM patients typically show high propensity to recur as the cancer cells express-
ing KCNMA1v might survive surgical and therapeutic treatment. The xenograft tumors in 
mice likewise demonstrated increased growth, which correlated well with Ki-67 expression 
(under publication). The overexpression of KCNMA1v resulted in increased angiogenesis in 
the tumor xenografts, supporting the angiogenic role of KCNMA1v. The observation that the 
overexpression of KCNMA1v in human gliomas correlates with increased angiogenesis in 
high-grade gliomas further supports that KCNMA1 splicing event is an important biological 
process for glioma progression. Consistent with this observation, we found that glioma cells 
over-expressing KCNMA1v secreted significantly the high level of angiogenic factor VEGF 
(under publication).
6. Conclusion
Further investigation into the mechanisms and cellular events caused by KCNMA1 splic-
ing may lead to the development of future therapies for this highly deadly disease. Splice 
variants that are found in high-grade gliomas have clear diagnostic and prognostic values 
besides providing potential targets for anticancer drug development. Clinical outcome 
of KCNMA1v expression in high-grade glioma is expected to reveal the variants’ clinical 
importance. This analysis is being performed in our laboratory. In conclusion, the results 
presented here might suggest that quantifying the levels of KCNMA1v could be useful to 
identify biological process that increases the malignancy and affect prognosis of high-grade 
glioma patients.
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